Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, Montero M, Galindo MJ, Muñoz-Sánchez MJ, Espinosa N, Peraire J, Martínez E, de la Fuente B, Domingo P, Deig E, Merino MD, Geijo P, Estrada V, Sepúlveda MA, García J, Berenguer J, Currán A. Teira R, et al. Among authors: de la fuente b. Infect Dis Ther. 2022 Jun;11(3):1177-1192. doi: 10.1007/s40121-022-00630-y. Epub 2022 Apr 11. Infect Dis Ther. 2022. PMID: 35399147 Free PMC article.
Hepatitis C virus and human immunodeficiency virus coinfection in Spain.
Roca B, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, Geijo P, Cosin J, Perez-Cortes S, Galindo MJ, Lozano F, Domingo P, Viciana P, Ribera E, Vergara A, Sánchez T. Roca B, et al. Among authors: de la fuente b. J Infect. 2003 Aug;47(2):117-24. doi: 10.1016/s0163-4453(03)00067-7. J Infect. 2003. PMID: 12860144
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.
Berenguer J, Jarrín I, Pérez-Latorre L, Hontañón V, Vivancos MJ, Navarro J, Téllez MJ, Guardiola JM, Iribarren JA, Rivero-Juárez A, Márquez M, Artero A, Morano L, Santos I, Moreno J, Fariñas MC, Galindo MJ, Hernando MA, Montero M, Cifuentes C, Domingo P, Sanz J, Domíngez L, Ferrero OL, De la Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, Losa JE, Vilaró J, Bernal E, Arponen S, Ortí AJ, Chocarro Á, Teira R, Alonso G, Silvariño R, Vegas A, Geijo P, Bisbe J, Esteban H, González-García J; GeSIDA 8514 Study Group. Berenguer J, et al. Among authors: de la fuente b. Open Forum Infect Dis. 2018 Jan 12;5(1):ofx258. doi: 10.1093/ofid/ofx258. eCollection 2018 Jan. Open Forum Infect Dis. 2018. PMID: 29354658 Free PMC article.
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV.
Teira R, Diaz-Cuervo H, Aragão F, Marguet S, de la Fuente B, Muñoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martínez E, Geijo P, Estrada V, García J, Sepúlveda MA, Berenguer J. Teira R, et al. Among authors: de la fuente b. PLoS One. 2021 Apr 8;16(4):e0249515. doi: 10.1371/journal.pone.0249515. eCollection 2021. PLoS One. 2021. PMID: 33831047 Free PMC article.
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, De La Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, De Miguel M, Jarrín I, González-García J; GeSIDA 8514 Study Group. Pérez-Latorre L, et al. Among authors: de miguel m, de la fuente b. Euro Surveill. 2021 Jun;26(25):2000236. doi: 10.2807/1560-7917.ES.2021.26.25.2000236. Euro Surveill. 2021. PMID: 34169818 Free PMC article.
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
Teira R, Diaz-Cuervo H, Aragão F, Muñoz J, Galindo P, Merino M, de la Fuente B, Sepúlveda MA, Domingo P, García J, Castaño M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martínez E, Estrada V, Montero M, Berenguer J, Espinosa N. Teira R, et al. Among authors: de la fuente b. HIV Res Clin Pract. 2021 Jun;22(3):78-85. Epub 2021 Aug 19. HIV Res Clin Pract. 2021. PMID: 34410219
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J; GeSIDA 8514 Study Group. Fanciulli C, et al. Among authors: de miguel m, de la fuente b. HIV Med. 2022 Aug;23(7):705-716. doi: 10.1111/hiv.13229. Epub 2022 Jan 17. HIV Med. 2022. PMID: 35037379 Free PMC article.
129 results